Additionally, the introduction of novel anti-diabetic medications like glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose transport protein 2 (SGLT2) inhibitors, along with advancements in managing chronic conditions like hypertension and DM, may have contributed to improving overall health outcomes during this period [23]. This evidence concerns the gene GCG and hypertensive disorder.